Aurora closes new multimillion-dollar deal with MedReleaf

It was a deal that amounted to US$2 billion for the purchase of a majority stake in MedReleaf. The regulation of cannabis, whether medicinal or for recreational purposes, is being the reason for strategic agreements between several companies, which thus initiate the positioning in the five continents.  

A Aurora and MedReleaf were two competing companies in the Canadian medical cannabis market. However, and according to July 6th press release, the Canadian regulator similar to the Securities and Exchange Commission gave the green light to [stock_quote symbol=”ACBFF” show=”name” decimals=”2″ number_format=”cd” template=”%company%:%exch_symbol% ​​(%change%%)” raw=”” class=””] for the acquisition of a majority stake in the [stock_quote symbol=”MEDFF” show=”name” decimals=”2″ number_format=”cd” template=”%company%:%exch_symbol% ​​(%change%%)” raw=”” class=””].

Aurora Cannabis diversifies into several subsidiaries with different roles and functions.

Aurora bought MedReleaf shares for a unit price of 29,44 Canadian dollars, an amount higher than the value defined at the end of the previous day's trading, on the Toronto Stock Exchange (TSX), by 18,2 percent.